Early-Stage Developability Assessment for Lead Optimization

Early-stage biologics discovery often focuses on binding affinity, while other developability attributes that affect downstream success are sometimes overlooked. Incorporating early developability assessment can help identify and mitigate potential liabilities in the pipeline. This webinar will introduce the Micro Developability platform, a high-throughput analytical suite designed to assess key developability attributes using minimal protein input. The platform evaluates PK (self-association, non-specific binding, FcRn affinity, and serum stability), biophysical properties, stability, and immunogenicity. Through modality-driven study design, real-world case studies, and data interpretation, you will learn how these assessments guide lead optimization, mitigate downstream risks, and facilitate smoother progression from research to development. In this webinar, you will discover: • Recently updated, integrated early developability panel combining in silico modelling and in vitro assays • High-throughput, robust, and highly sensitive assays for PK and biophysical assessment • Advanced immunogenicity assays specifically developed for early-stage lead evaluation • Purpose-driven forced degradation studies designed to support risk mitigation and closed-loop decision making